These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

909 related articles for article (PubMed ID: 34492082)

  • 1. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate.
    Jung BK; An YH; Jang JJ; Jeon JH; Jang SH; Jang H
    PLoS One; 2022; 17(2):e0263684. PubMed ID: 35134091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
    Ellis D; Brunette N; Crawford KHD; Walls AC; Pham MN; Chen C; Herpoldt KL; Fiala B; Murphy M; Pettie D; Kraft JC; Malone KD; Navarro MJ; Ogohara C; Kepl E; Ravichandran R; Sydeman C; Ahlrichs M; Johnson M; Blackstone A; Carter L; Starr TN; Greaney AJ; Lee KK; Veesler D; Bloom JD; King NP
    Front Immunol; 2021; 12():710263. PubMed ID: 34267764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
    Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
    Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2.
    Sun S; Cai Y; Song TZ; Pu Y; Cheng L; Xu H; Sun J; Meng C; Lin Y; Huang H; Zhao F; Zhang S; Gao Y; Han JB; Feng XL; Yu DD; Zhu Y; Gao P; Tang H; Zhao J; Zhang Z; Yang J; Hu Z; Fu YX; Zheng YT; Peng H
    Cell Res; 2021 Sep; 31(9):1011-1023. PubMed ID: 34267349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
    Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
    mBio; 2021 May; 12(3):. PubMed ID: 33975938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
    Tan TK; Rijal P; Rahikainen R; Keeble AH; Schimanski L; Hussain S; Harvey R; Hayes JWP; Edwards JC; McLean RK; Martini V; Pedrera M; Thakur N; Conceicao C; Dietrich I; Shelton H; Ludi A; Wilsden G; Browning C; Zagrajek AK; Bialy D; Bhat S; Stevenson-Leggett P; Hollinghurst P; Tully M; Moffat K; Chiu C; Waters R; Gray A; Azhar M; Mioulet V; Newman J; Asfor AS; Burman A; Crossley S; Hammond JA; Tchilian E; Charleston B; Bailey D; Tuthill TJ; Graham SP; Duyvesteyn HME; Malinauskas T; Huo J; Tree JA; Buttigieg KR; Owens RJ; Carroll MW; Daniels RS; McCauley JW; Stuart DI; Huang KA; Howarth M; Townsend AR
    Nat Commun; 2021 Jan; 12(1):542. PubMed ID: 33483491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS-CoV-2 neutralization.
    de Lima VA; Nunes JPS; Rosa DS; Ferreira R; Oliva MLV; Andreata-Santos R; Duarte-Barbosa M; Janini LMR; Maricato JT; Akamatsu MA; Ho PL; Schenkman S
    Immun Inflamm Dis; 2024 Jul; 12(7):e1353. PubMed ID: 39056544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam.
    Nguyen HT; Falzarano D; Gerdts V; Liu Q
    Microbiol Spectr; 2024 Aug; 12(8):e0095924. PubMed ID: 38916311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
    Jearanaiwitayakul T; Sunintaboon P; Kittiayuwat A; Limthongkul J; Wathanaphol J; Janhirun Y; Lerdsamran H; Wiriyarat W; Ubol S
    Vaccine; 2024 Jun; 42(17):3664-3673. PubMed ID: 38714446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
    Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
    ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate Vaccination.
    Huang WC; Zhou S; He X; Chiem K; Mabrouk MT; Nissly RH; Bird IM; Strauss M; Sambhara S; Ortega J; Wohlfert EA; Martinez-Sobrido L; Kuchipudi SV; Davidson BA; Lovell JF
    Adv Mater; 2020 Dec; 32(50):e2005637. PubMed ID: 33111375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
    Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
    Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Huang J; Wang W; Li H; Bai Y; Song Y; Jiao C; Jin H; Huang P; Zhang H; Xia X; Yan F; Li Y; Wang H
    Antiviral Res; 2024 Jul; 227():105905. PubMed ID: 38740191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
    Cohen AA; Gnanapragasam PNP; Lee YE; Hoffman PR; Ou S; Kakutani LM; Keeffe JR; Wu HJ; Howarth M; West AP; Barnes CO; Nussenzweig MC; Bjorkman PJ
    Science; 2021 Feb; 371(6530):735-741. PubMed ID: 33436524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.